Bharat Biotech dossier under review for Covaxin EUL, says WHO

Published On 2021-07-20 06:20 GMT | Update On 2021-07-20 06:20 GMT

New Delhi: Officials of the World Health Organisation (WHO) had a meeting with those of Bharat Biotech and the Hyderabad-based vaccine maker's dossier for Emergency Use Listing (EUL) of Covaxin is under review by the technical experts for consideration, Dr Poonam Khetrapal Singh, Regional Director, WHO South-East Asia said on Monday.

Speaking to ANI, Dr Singh also informed that India has been offered 7.5 million doses of Moderna vaccine through WHO's COVID-19 Vaccines Global Access (COVAX) program.

The WHO Regional Director said, "Pfizer, AstraZeneca, Moderna, Johnson and Johnson, Sinovac and Sinopharm have been granted EUL by the WHO. For COVAXIN, an expression of interest for EUL has been made to WHO by Bharat Biotech. WHO has already conducted a pre-submission meeting with the company following which a dossier has been submitted by Bharat Biotech to WHO in early July. The dossier is currently under review by the technical experts for consideration of EUL."

Cautioning about the possibility of the Delta variant of coronavirus becoming the most dominant COVID strain, Dr Singh said, "Delta variant has spread to over 100 countries, the way its spreading is likely to soon become the most dominant COVID strain globally."

"Among all variants of concern, Delta spreads most rapidly. The rapid spread means more cases, leading to more pressure on health systems and more deaths," she said.The WHO South-East Asia director noted that globally, COVID cases and fatalities were again on the rise.

"The more we allow the virus to spread, the more it will evolve, resulting in more variants. We need to ensure that public health and social measures are implemented continuously. The interventions proven to be effective even against the delta variant," she said.

Dr Singh also urged people to act 'urgently' to contain the spread of the COVID-19 virus and aggressively scale up vaccination especially of the vulnerable population for containment of the possible third wave.

"People are longing to go back to their normal lives which is understandable. However, we have to be reminded of the huge risk of letting our guards down. We witnessed that very recently and continue to do so globally even today. If we take the precautions, get vaccinated and leave no room for the virus to infect us, all of us together can contain the spread of the virus," she noted.

She further informed that for the past ten consecutive weeks, COVID cases have been continuously increasing in some Eastern Mediterranean, European and Southeast Asian countries.

Dr Singh also noted that cases are on a decline in India, Nepal, and Maldives. "However, the situation continues to be a concern,' she said.

"The pandemic isn't over anywhere. We must continue to strengthen our capacity. There is absolutely no room for complacency. We need to prevent another surge and scale up our response capacity along with our vaccination programmes," she added.

Article Source : ANI

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Ruchika Sharma

Ruchika Sharma joined Medical Dialogue as an Correspondent for the Business Section in 2019. She covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She has completed her B.Com from Delhi University and then pursued postgraduation in M.Com. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751

Comments Policy

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Bharat Biotech dossier under review for Covaxin EUL, says WHO

Similar News

Roche Slammed for Seeking Zydus' Confidential Process for Cancer Drug Sigrima Without Meeting Patent Threshold

Ranitidine Under Cancer Cloud: CDSCO Calls for Monitoring NDMA Levels, Shelf Life Cuts

E-Pharmacy Threat Growing Unchecked: AIOCD Flags Regulatory Failure, Calls for Urgent CDSCO Action

Dr Reddys Labs invests Rs 565 crore in Russian subsidiary

Senores Pharma arm facility gets 3 USFDA observations

Lupin, Sun Pharma and 1 other recall products in US

Odisha: Huge cache of banned cough syrups seized, 3 arrested

Andhra Pradesh allots 531.77 acres of land to Laurus Labs